Table 1 Clinicopathological features of 332 patients who had surgery after being diagnosed with cT1N0-2 M0 breast cancer, including 319 cT1N0M0 breast cancer
From: Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer
Parameters | Number of all patients (n = 332) (%) | Number of cN0 patients (n = 319) (%) |
|---|---|---|
Age at operation (years old) | median 59 (range, 29–79) | median 59 (range, 29–79) |
Tumor size (mm) | median 13 (range, 4–20) | median 13 (range, 4–20) |
Clinical lymph node metastasis cN0 / cN1 / cN2 | 319 (96.1%) / 11 (3.3%) / 2 (0.6%) | – |
Estrogen receptor Negative / Positive | 59 (17.8%) / 273 (82.2%) | 57 (17.9%) / 262 (82.1%) |
Progesterone receptor Negative / Positive | 130 (39.2%) / 202 (60.8%) | 125 (39.2%) / 194 (60.8%) |
HER2 Negative / Positive | 306 (92.2%) / 26 (7.8%) | 295 (92.5%) / 24 (7.5%) |
Ki67 ≤ 14% / > 14% | 206 (62.0%) / 126 (38.0%) | 196 (61.4%) / 123 (38.6%) |
Intrinsic subtype HR + HER2-BC / HR + HER2 + BC / HER2enriched BC / TNBC | 265 (79.8%) / 11 (3.3%) / 15 | 255 (79.9%) / 10 (3.1%) / 14 |
(4.5%) / 41 (12.4%) | (4.4%) / 40 (12.6%) | |
Lymphatic invasion ly0 / ly1 | 229 (69.0%) / 103 (31.0%) | 224 (70.2%) / 95 (29.8%) |
Venous invasion v0 / v1 | 318 (95.8%) / 14 (4.2%) | 306 (95.9%) / 13 (4.1%) |
Nuclear grade 1 / 2 / 3 | 164 (49.4%) / 129 (38.9%) / 39 | 158 (49.5%) / 125 (39.2%) / 36 |
(11.7%) | (11.3%) | |
Pathological lymph node metastasis pN0 / pN1mic / pN1a / pN2 | 257 (77.4%) / 16 (4.8%) / 54 | 257 (80.6%) / 16 (5.0%) / 46 |
(16.3%) / 5 (1.5%) | (14.4%) / 0 (0.0%) | |
TILs (score) 0 / 1 / 2 / 3 | 29 (8.7%) / 243 (73.2%) / 57 | 25 (7.8%) / 235 (73.7%) / 56 |
(17.2%) / 3 (0.9%) | (17.6%) / 3 (0.9%) |